Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 2/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1503774 | 0.80 | BTK (0.40) | RORCBTKMAOBKDM1ACTSK | |
| SCHEMBL1503741 | 0.79 | BTK (0.42) | RORCBTKMAOBKDM1ACTSK | |
| SCHEMBL14259181 | 0.77 | BTK (0.44) | BTKMAOBKDM1AMAOACTSK | |
| SCHEMBL741205 | 0.77 | BTK (0.41) | BTKMAOBKDM1AMAOACTSK | |
| SCHEMBL12531979 | 0.77 | BTK (0.41) | BTKMAOBKDM1AMAOACTSK | |
| SCHEMBL16095542 | 0.77 | BTK (0.44) | BTKMAOBKDM1AMAOACTSK | |
| SCHEMBL4690514 | 0.77 | BTK (0.44) | BTKMAOBKDM1AMAOACTSK | |
| SCHEMBL5430323 | 0.77 | BTK (0.44) | BTKMAOBKDM1AMAOACTSK | |
| SCHEMBL741204 | 0.77 | BTK (0.41) | BTKMAOBKDM1AMAOACTSK | |
| SCHEMBL20063737 | 0.77 | BTK (0.41) | BTKMAOBKDM1AMAOACTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093785-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | RORC 3962/4885BTK 1281/4885MAOB 2147/4885 |
| US-20100093785-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | RORC 3397/4885BTK 1117/4885MAOB 2668/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | RORC 3962/4885BTK 1281/4885MAOB 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.